Codexis to exhibit at CPhI Worldwide 2017

Published: 29-Sep-2017
Ingredients Pharmaceutical Active Nutrition Food

Codexis is leading the way with powerful biocatalysts that integrate biology and chemistry

Unlock the power of proteinsTM

Codexis, Inc. is a leading protein engineering company that applies its revolutionary CodeEvolver® platform technology to deliver high-performing enzymes for improving the cost and quality of pharmaceuticals and food ingredients, to enable sequencing of minute quantities of DNA for medical diagnostics and to create novel biotherapeutics.

Since 2002, the protein engineering experts at Codexis have created unique solutions — solutions others may not even contemplate, let alone successfully execute for a wide range of industries.

Meet Codexis at CPhI WW 2017; stand 111F53

  • Companies:
  • Codexis
See more

You may also like

Ingredients

Nestlé tackles phenylketonuria with Codexis enzyme

Read more
Codexis announces that Nestlé Health Science has exercised its option to obtain an exclusive license for the global development and commercialisation of the orally delivered enzyme CDX-6114 for the management of phenylketonuria (PKU)

Trending Articles

  1. Get ahead in the pharmaceutical industry with a Manufacturing Chemist subscription With a Manufacturing Chemist subscription you receive exclusive access to the latest news, technical insights, regulatory updates, and market intelligence
  2. Theranexus and Exeltis sign commercialisation agreement for neurological disorder-targeting TX01 The therapeutic will be used to target Gaucher and Niemann-Pick type C, with Exeltis attaining the exclusive rights to the marketing and distribution of TX01 across the Europe, South America and the Middle East
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    Merck jumps on the GLP-1 therapeutic bandwagon by licensing Hansoh Pharma's HS-10535 Merck will be responsible for the development, manufacture and commercialisation of the investigational preclinical oral GLP-1 receptor agonist
  4. Novo Nordisk invests DKK 8.5bn into new Danish modular production site This is the first time this century that Novo Nordisk has invested into its Danish production capabilities, with the site being capable of manufacturing product types within rare disease indications

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Ingredients

Nestlé tackles phenylketonuria with Codexis enzyme

Codexis announces that Nestlé Health Science has exercised its option to obtain an exclusive license for the global development and commercialisation of the orally delivered enzyme CDX-6114 for the management of phenylketonuria (PKU)
Ingredients

Global partnership to expand pharma biocatalysis uptake

Codexis, Inc. and Porton Pharma Solutions recently announced a strategic collaboration to deploy Codexis’ world-leading biocatalyst technology within Porton’s global custom intermediate and active pharmaceutical ingredients (API) development and manufacturing business. Dr Kevin Robinson caught up with Porton’s Oliver Ju and Codexis’ John Nicols to find our more
Pharmaceutical

Riding the wave of protein revolution

Optimised biocatalysts for the pharmaceutical and food industries
Manufacturing

Porton Pharma Solutions and Codexis launch global partnership

The partnership reinforces the benefits of reduced costs, enhanced sustainability and improved product quality that biocatalysts can deliver to the manufacturing of the world's small molecule pharmaceuticals
Ingredients

Codexis reports loss of US$7m in Q1

Revenue increased by 18% to $8m after significant growth in core biocatalyst R&D revenues and product sales
Manufacturing

Codexis reports 2015 fourth quarter and full year financial results

Financial outlook for 2016 is for another year of growth with revenues in the range of US$46–49m
Ingredients

Codexis files lawsuit against EnzymeWorks and its founder over alleged patent infringement

US developer of biocatalysts also alleges that Junhua (Alex) Tao misappropriated trade secrets
Subscribe now